Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI Demand

Key Points

• Aehr Test Systems shares jumped 26.5% after it reported Q1 FY2027 revenue of $33 million, tripling year-over-year and beating estimates, prompting raised full-year guidance to $150 million.
• A large order backlog of $109.3 million and strong quarterly bookings of $46.7 million suggest Aehr is well-positioned to meet or exceed its raised revenue outlook.
• Despite strong momentum and a potentially major new customer opportunity, Aehr faces risks from AI spending volatility, an elevated valuation, and heavy reliance on just two customers.

AI stocks have experienced dramatic volatility over recent trading sessions. However, as investors weigh whether Democratic midterm victories could slow the AI infrastructure buildout, Aehr Test Systems NASDAQ: AEHR is one company whose latest results point to continued demand.

The small-cap semiconductor testing equipment stock recently reported its latest earnings and recorded another big win. Aehr gained 26.5% the day after its report, marking the fourth consecutive quarter in which shares have risen 15% or more post-earnings.

While the company continues to outperform expectations and has large potential opportunities on the horizon, risk remains a key consideration.

Aehr Grows by 200%, Raises Full-Year Guidance

Aehr posted revenue of $33 million in the first quarter of its fiscal year 2027 (FY2027). The company’s fiscal reporting period is ahead of the standard cadence used by many companies. Sales tripled year-over-year (YOY) from $11 million and handily beat estimates near $27.5 million.

Adjusted earnings per share (EPS) also soared, coming in at 28 cents compared to 1 cent a year ago and 11 cents last quarter. EPS also smashed expectations of 11 cents. Meanwhile, diluted GAAP EPS rose from a loss of 7 cents last year to a profit of 21 cents, and Aehr’s adjusted gross margin climbed 11 percentage points to 48.5%.

Bookings were even stronger than sales, coming in at $46.7 million, representing a book-to-bill ratio of 1.4. Effective backlog, including bookings received after quarter end, was $109.3 million.

Amid this strong demand momentum, Aehr substantially raised the midpoint of its full-year FY2027 guidance. The company now expects to generate sales of $150 million, 7.1% above its previous midpoint guidance of $140 million, implying full-year growth of 200%. The company also expects to generate adjusted net income equal to at least 20% of its revenue. If Aehr achieves both its sales and margin guidance, it would generate at least $30 million in adjusted net income, compared to less than $1 million last year.

Aehr’s 2027 Guidance Looks to Be on Solid Footing

Just because a company sets an outlook does not mean it will achieve it, but several factors point to Aehr being in a strong position to hit its revenue guidance. The company has already recognized $33 million in revenue, leaving a $117 million gap with its $150 million outlook. However, Aehr also already has a large effective order backlog of $109.3 million. Assuming the company delivers this entire backlog in its FY2027, its sales would be $142.3 million. In other words, Aehr would only need to generate and deliver new orders worth $7.7 million to hit its $150 million target. Lake Street analyst Max Michaelis pointed this out on Aehr’s earnings call and said that the guidance felt “almost conservative.”

In response, Aehr’s CEO Gayn Erickson noted that the company is “trying to be conservative” and implied that Aehr’s backlog delivery timeline maps closely to FY2027. Erickson also said that the company is not supply constrained, and that it could ship more than $150 million if it generates more orders. Notably, Aehr generated $46.7 million of orders in Q1 alone, roughly six times the $7.7 million in additional orders needed under that assumption. This order volume suggests that Aehr is in a strong position to meet its raised outlook and that this outlook could still be conservative.

Looking further out, Aehr says it has made “significant progress with a major supplier of AI accelerators, CPUs and network processors.” Aehr says the supplier has agreed to purchase a FOX-XP burn-in system for installation in early calendar 2027 for evaluation in a high-volume production environment. In the following months, this company will then decide whether to make a larger order. Aehr notes that this is one of the largest potential burn-in opportunities it has ever pursued. While still an opportunity rather than a confirmed production order, Aehr’s strong language suggests that it could translate into very significant sales volume if successful.

Aehr: Big-Time Demand, Significant Risks

While Aehr has a lot going for it, there are several key risk factors that make proceeding with caution around this high-volatility name critical. First off, should fears of an AI buildout slowdown intensify, Aehr could face significant selling pressure. Notably, shares plummeted 19.2% on Nov. 5 during a broader sell-off in AI-related stocks.

Additionally, Aehr trades at an elevated forward price-to-sales (P/S) ratio of around 12x. Although this multiple has fallen from earlier highs, it still leaves little room for missed growth expectations.

Finally, at this point, Aehr has a highly concentrated customer base. Last quarter, nearly 73% of Aehr’s sales came from just two customers. Should these relationships take a hit, it could significantly damage Aehr’s long-term outlook. Still, the potential that Aehr could win one of its largest customers ever provides a path to mitigating concentration concerns.